Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PVCT | US
-0.01
-5.26%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
30/08/2024
0.09
0.09
0.10
0.09
Provectus Biopharmaceuticals Inc. a clinical-stage biotechnology company engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers as well as refractory and relapsed pediatric and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development wound healing and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals Inc. and changed its name to Provectus Biopharmaceuticals Inc. in December 2013. Provectus Biopharmaceuticals Inc. was founded in 2002 and is based in Knoxville Tennessee.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
105.4%1 month
155.8%3 months
139.8%6 months
115.8%-
-
5.44
-
-
-18.78
142.31
-
-2.05M
38.93M
38.93M
-
-254.48
-
57.60
-
0.47
0.78
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.03
Range1M
0.08
Range3M
0.14
Rel. volume
4.77
Price X volume
46.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3596 | 27.20M | 1.38% | n/a | 4.33% |
MEI Pharma Inc | MEIP | Drug Manufacturers-Specialty & Generic | 3.1 | 20.65M | -4.91% | 0.79 | 22.86% |
Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 3.67 | 19.63M | 2.23% | n/a | 0.00% |
Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 1.35 | 19.03M | -0.74% | n/a | 81.86% |
Guardion Health Sciences Inc | GHSI | Drug Manufacturers-Specialty & Generic | 13.87 | 17.81M | 5.80% | n/a | 0.00% |
Flora Growth Corp. Common Stock | FLGC | Drug Manufacturers-Specialty & Generic | 1.03 | 13.77M | 0.00% | n/a | 76.81% |
Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 1.09 | 6.04M | -1.36% | n/a | 13.20% |
Imc Mortgage Co | IMCC | Drug Manufacturers-Specialty & Generic | 2.44 | 5.48M | -2.40% | n/a | 222.75% |
SHPH | SHPH | Drug Manufacturers-Specialty & Generic | 1.93 | 4.05M | 4.61% | n/a | 144.16% |
Avenue Therapeutics Inc | ATXI | Drug Manufacturers-Specialty & Generic | 2.54 | 3.64M | 0.79% | 0.08 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.76 | 11.69M | 7.80% | n/a | 422.08% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.97% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 14.28 | 0 | -0.07% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -18.78 | - | Cheaper |
Ent. to Revenue | 142.31 | - | Cheaper |
PE Ratio | - | 28.13 | - |
Price to Book | 5.44 | 11.07 | Cheaper |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 139.75 | - | Riskier |
Debt to Equity | - | -0.91 | - |
Debt to Assets | - | 0.45 | - |
Market Cap | 38.93M | - | Emerging |